Ligand Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Ligand Pharmaceuticals's earnings have been declining at an average annual rate of -58.9%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 0.5% per year. Ligand Pharmaceuticals's return on equity is 5.4%, and it has net margins of 31.6%.
Key information
-58.9%
Earnings growth rate
-54.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 0.5% |
Return on equity | 5.4% |
Net Margin | 31.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Revenue & Expenses Breakdown
How Ligand Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 133 | 42 | 59 | 0 |
31 Mar 24 | 118 | 96 | 53 | 0 |
31 Dec 23 | 131 | 54 | 53 | 0 |
30 Sep 23 | 154 | 21 | 68 | 10 |
30 Jun 23 | 180 | 41 | 68 | 10 |
31 Mar 23 | 204 | 51 | 69 | 0 |
31 Dec 22 | 196 | -5 | 70 | 0 |
30 Sep 22 | 183 | 23 | 46 | 0 |
30 Jun 22 | 188 | 27 | 44 | 0 |
31 Mar 22 | 223 | 45 | 46 | 0 |
31 Dec 21 | 242 | 76 | 47 | 0 |
30 Sep 21 | 275 | 68 | 49 | 0 |
30 Jun 21 | 252 | 48 | 51 | 0 |
31 Mar 21 | 208 | 39 | 47 | 0 |
31 Dec 20 | 164 | 7 | 39 | 0 |
30 Sep 20 | 143 | -16 | 45 | 0 |
30 Jun 20 | 126 | -25 | 39 | 0 |
31 Mar 20 | 110 | -61 | 40 | 0 |
31 Dec 19 | 120 | 629 | 42 | 0 |
30 Sep 19 | 153 | 594 | 43 | 0 |
30 Jun 19 | 174 | 677 | 43 | 0 |
31 Mar 19 | 239 | 764 | 41 | 0 |
31 Dec 18 | 251 | 143 | 38 | 0 |
30 Sep 18 | 242 | 179 | 34 | 0 |
30 Jun 18 | 230 | 120 | 32 | 0 |
31 Mar 18 | 168 | 53 | 29 | 0 |
31 Dec 17 | 141 | 13 | 29 | 0 |
30 Sep 17 | 129 | 16 | 28 | 0 |
30 Jun 17 | 117 | 9 | 27 | 0 |
31 Mar 17 | 109 | -3 | 28 | 0 |
31 Dec 16 | 109 | -2 | 28 | 0 |
30 Sep 16 | 92 | 7 | 27 | 0 |
30 Jun 16 | 88 | 205 | 25 | 0 |
31 Mar 16 | 87 | 235 | 25 | 0 |
31 Dec 15 | 72 | 230 | 25 | 0 |
30 Sep 15 | 74 | 231 | 24 | 0 |
30 Jun 15 | 71 | 33 | 25 | 0 |
31 Mar 15 | 63 | 11 | 23 | 0 |
31 Dec 14 | 65 | 12 | 23 | 0 |
30 Sep 14 | 56 | 7 | 21 | 0 |
30 Jun 14 | 54 | 8 | 19 | 0 |
31 Mar 14 | 53 | 10 | 19 | 0 |
31 Dec 13 | 49 | 9 | 18 | 0 |
30 Sep 13 | 48 | 10 | 18 | 0 |
Quality Earnings: LGND has a large one-off gain of $74.1M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: LGND's current net profit margins (31.6%) are higher than last year (22.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LGND's earnings have declined by 58.9% per year over the past 5 years.
Accelerating Growth: LGND's earnings growth over the past year (2.8%) exceeds its 5-year average (-58.9% per year).
Earnings vs Industry: LGND earnings growth over the past year (2.8%) did not outperform the Pharmaceuticals industry 13%.
Return on Equity
High ROE: LGND's Return on Equity (5.4%) is considered low.